Quantification of the HA-1 gene product at the RNA level; relevance for immunotherapy of hematological malignancies

Hematology Journal

Volumn 4, Issue 5, 2003, Pages 315-320

  Wilke, Martina ^a   Dolstra, Harry ^b   Maas, Frans ^b   Pool, Jos ^a   Brouwer, Rolf ^a   Falkenburg, J H Frederik ^a   Rebello, Ashok ^a   Lamers, Femke ^a   Schuuring, Ed ^a   Kluin, Philip ^a   Brasseur, Francis ^c   Goulmy, Els ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

Author keywords

Hematological malignancies; Hematopoietic restricted expression; Immunotherapy; Minor histocompatibility antigens; Quantitative PCR

Indexed keywords

CD45 ANTIGEN; GENE PRODUCT; MINOR HISTOCOMPATIBILITY ANTIGEN; RNA;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HEMATOPOIETIC SYSTEM; HLA MATCHING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LEUKEMIA; RISK ASSESSMENT; RNA ANALYSIS; STEM CELL TRANSPLANTATION;

ANTIGENS, CD45; CELLS, CULTURED; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES; MINOR HISTOCOMPATIBILITY ANTIGENS; OLIGOPEPTIDES; POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE DISTRIBUTION;

EID: 12444326266     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200318     Document Type: Article

References (29)

1. Horowitz MM, Truitt RL. Graft versus leukemia effects of hematopoietic stem cell transplantation. In: Attkinson K (ed). Clinical Bone Marrow and Blood Stem Cell Transplantation. Cambridge University Press: Cambridge, 2000, p 1327-1338.
2. Butturini A, Gale RP. T cell depletion in bone marrow transplantation for leukemia: current results and future directions. Bone Marrow Transplant 1988; 3: 185-192.
3. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806-814.
4. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
5. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
6. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 1997; 157: 125-140.
7. de Bueger M, Bakker A, van Rood JJ, Van der Woude WF, Goulmy E. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 1992; 149: 1788-1794.
8. van der Harst D, Goulmy E, Falkenburg JHF, Kooij-Winkelaar YM, Luxemburg-Heijs SA, Goselink HM et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T cell clones. Blood 1994; 83: 1060-1066.
9. Falkenburg JHF, Goselink HM, van der HD, Luxemburg-Heijs SA, Kooy-Winkelaar YM, Faber LM et al. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med 1991; 174: 27-33.
10. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
11. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195.
12. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
13. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999; 93: 2336-2341.
14. Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JHF, Vossen J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996; 334: 281-285.
15. Tseng LH, Lin MT, Hansen JA, Gooley T, Pei J, Smith AG et al. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1999; 94: 2911-2914.
16. van Lochem E, van der Keur M, Mommaas AM, de Gast GC, Goulmy E. Functional expression of minor histocompatibility antigens on human peripheral blood dendritic cells and epidermal Langerhans cells. Transpl Immunol 1996; 4: 151-157.
17. de Boer CJ, van Krieken JH, Kluin-Nelemans HC, Kluin PM, Schuuring E. Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma. Oncogene 1995; 10: 1833-1840.
18. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996; 6: 995-1001.
19. Higuchi R, Fockler C, Dollinger G, Watson R. Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology (NY) 1993; 11: 1026-1030.
20. Thomas ML, Brown EJ. Positive and negative regulation of Src-family membrane kinases by CD45. Immunol Today 1999; 20: 406-411.
21. Thomas ML, Lefrancois L. Differential expression of the leucocyte-common antigen family. Immunol Today 1988; 9: 320-326.
22. Chretien S, Dubart A, Beaupain D, Raich N, Grandchamp B, Rosa J et al. Alternative transcription and splicing of the human porphobilinogen deaminase gene result either in tissue-specific or in housekeeping expression. Proc Natl Acad Sci USA 1988; 85: 6-10.
23. den Haan JM, Meadows LM, Wang W, Pool J, Blokland E, Bishop TL et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 1998; 279: 1054-1057.
24. Dolstra H, Fredrix H, Maas F, Coulie PG, Brasseur F, Mensink E et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med 1999; 189: 301-308.
25. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330: 100-106.
26. Fujii N, Hiraki A, Ikeda K, Ohmura I, Nazali K, Shinagawa K et al. Expression of minor histocompatibility antigen, HA-1, in solid tumor cells. Transplantation 2002; 73: 1137-1141.
27. Ferrara JL. Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opin Immunol 1993; 5: 794-799.
28. Dickinson AM, Wang XN, Sviland L, Vyth-Dreese FA, Jackson GH, Schuhmacher TNM et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 2002; 8: 410-414.
29. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-415.